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      ”The rabbit runs faster than the fox,  
   because the rabbit is running for his life 
while the fox is only running for his dinner” 
      Richard Dawkins, The Selfish Gene 
  
 
 
  
ABSTRACT 
Skeletal dysplasias constitute a large and heterogeneous group of disorders, many causing 
disabilities with profound effects on the quality of life of the affected individuals and their 
families. Each individual skeletal dysplasia is rare, however, as more than 450 different 
disorders have been described, skeletal dysplasias as a group affect approximately three in 
10 000 individuals. The age of onset for skeletal dysplasias ranges from prenatal to adult, but 
most of the affected individuals are diagnosed in childhood. Skeletal dysplasias mainly affect 
bone and cartilage, but symptoms may involve other organs, such as sensorineural hearing 
loss in Stickler syndrome, nephronophthisis in Sensenbrenner syndrome, and structural heart 
abnormalities in acromicric dysplasia. Therefore, most skeletal dysplasias can be defined as 
syndromes with a significant skeletal involvement. 
 
Clinical diagnosis of skeletal dysplasias is based on meticulous phenotypic characterization, 
skeletal radiography (for pattern recognition) and genetic testing. Molecular diagnostics has 
improved significantly by massively parallel sequencing (MPS) technologies, such as whole 
exome and genome sequencing. However, even after extensive clinical phenotyping and 
advanced molecular analyses, many patients with congenital skeletal disorders still lack 
molecular diagnoses and many clinical entities are not well-characterized regarding their 
natural course and complications. Molecular diagnosis is important since it gives information 
about prognosis and recurrence risk, as well as, in some cases possibilities to offer targeted 
treatment, participation in clinical trials, and tailored medical follow-up. This thesis focuses 
on gene discovery, studies of previously clinically defined skeletal dysplasias with unknown 
genetic background and aims to improve the molecular analyses for patients with diagnoses 
which are difficult to solve.  
 
In study I, we identify a novel pathogenic variant in ALG9, as the cause of a lethal skeletal 
syndrome in two families. In study II, we show that a variant in COL2A1 causes 
spondyloepiphyseal dysplasia type Stanescu. Study III shows that pathogenic variants in 
BMPER cause ischiospinal dysostosis (ISD), which is allelic to diaphanospondylodysostosis. 
In study IV, we describe a novel skeletal ciliopathy in four individuals with 
spondylometaphyseal dysplasia and thorax hypoplasia caused by pathogenic variants in 
KIAA0753. Finally, study V represents a cohort of 24 unrelated patients with skeletal 
ciliopathies, where we solve the genetic diagnoses in 83% of them. Here, we show two rare 
intronic variants and two exonic synonymous variants leading to aberrant splicing, which 
indicates that extended RNA studies are necessary to improve molecular diagnostics in some 
cases. 
 
Altogether, the results of these studies expand the genetic and phenotypic spectrum of 
skeletal dysplasias and demonstrate that MPS technology in combination with meticulous 
phenotyping is a powerful method to discover disease-causing variants in patients with 
congenital skeletal disorders.   
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1 INTRODUCTION 
1.1 SKELETAL DYSPLASIAS 
Skeletal dysplasias are a heterogeneous group of disorders primarily affecting the bone and 
connective tissues. The development and growth of the skeleton is tightly coordinated by the 
genetic program and abnormalities in skeletal signalling pathways lead to profound 
consequences for bone development. There are approximately 1 000 genes important for 
skeletal development and mutations in many of them lead to congenital skeletal disorders. 
Each single clinical entity of skeletal dysplasias is rare and altogether there are about 450 
conditions,1 many of them have not been well characterized yet and the molecular pathways 
for many of the reported conditions have not been explored in detail. 
 
Even though there is no general consensus on the definition of a rare disease, according to 
the European organization of rare disorders (EURORDIS; www.eurordis.org), a rare disorder 
is one that affects less than 1 in 2 000 individuals. In Sweden though, a rare disorder is defined 
as 1 in 10 000 (NFSD; www.nfsd.se). This means that a rare disorder may affect only a small 
percentage of patients in the world, while others affects as many as 200 000. Congenital 
skeletal disorders occur approximately in two to three in 10 000 individuals.2-4 Two common 
skeletal dysplasias are Leri-Weill dyschondrosteosis (LWD [MIM:127300]) affecting 
approximately 1:2 000 individuals and achondroplasia (ACH [MIM:100800]) with an 
incidence around 1:20 000. However, the prevalence is very different among skeletal 
dysplasias, with some of the them being extremely rare and so far only reported in a few 
individuals in the literature, for example al Gazali skeletal dysplasia5 and Saul-Wilson 
syndrome.6 
 
Genetic skeletal disorders include dysplasias, dysostoses, and osteolyses, and the distinction 
between these conditions is essential for accurate diagnosis. Skeletal dysplasias comprise a 
diverse group of diseases most often characterized by short stature due to abnormal growth 
of bones and cartilage organization or due to mineralization defects. The genes involved in 
skeletal dysplasias are thought to be constantly expressed from early embryonic stages 
throughout adulthood. In contrast, dysostoses are defects localized to a single skeletal 
component (or a few of them in combination), due to deficient regulatory factors only 
temporarily expressed during embryogenesis (within the first eight weeks of embryonic 
development). Skeletal dysplasias and dysostoses overlap, but skeletal dysplasias are more 
generic and usually progress as a result of the persistent expression of an affected gene 
through skeletal development and longitudinal bone growth. In osteolyses, on the other hand, 
the bone formation is normal at first, but then a process of progressive destruction or 
disappearance of bone tissue starts.7 
Skeletal dysplasias should per definition be distinguished from skeletal syndromes, since 
dysplasias occur in isolation (non-syndromic). In skeletal syndromes bone and cartilage 
abnormalities are associated with a broad spectrum of symptoms from other organs, such as 
hearing impairment, internal malformations or dysfunction of the immune system. However, 
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despite the above theoretical definitions, in clinical practice, the terms “skeletal dysplasia” 
or “skeletal disorder” are commonly used and these terms will be used in this thesis. 
 
1.1.1 Clinical presentation 
Careful clinical examination and detailed radiographic evaluation of the patients with 
congenital skeletal dysplasias are essential for correct diagnosis. Clinical examination 
includes morphological top-to-toe examination, skeletal survey, and often other imaging 
techniques when structural anomalies are suspected (such as ultrasound or MRI). Specific 
radiographic signs in combination with clinical findings, such as dysmorphic features, 
internal malformations or biochemical abnormalities usually lead to a diagnostic hypothesis, 
as exemplified in Figure 1. 
 
Figure 1. Examples of radiographic signs in patients with skeletal dysplasias. A. Fetus at GA 15 weeks 
(missed abortion) with kyphomelic dysplasia, poor bone mineralization, deformed skull, trunk, and short 
angulated bones. B. Fetus with short-rib thoracic dysplasia at 21 weeks GA (termination of pregnancy) with short 
ribs, short iliac bones, and trident pelvis. C. Hand shows brachydactyly and postaxial polydactyly. D. Radiographs 
of upper arm of an adult patient with De Hauwere syndrome, note gracile humerus, and elbow dislocation. E. 
Lower extremity radiograph of a 5-year-old child with Saul-Wilson syndrome with slender tubular bones with 
metaphyseal flaring and large epiphyses. GA, gestational age. 
 
Historically, classification of skeletal dysplasias was based on phenotypic and radiographic 
appearance. Upon the discovery of the genetic causes some of them were divided into groups 
according to the underlying genetic defects. Currently, some groups in the nosology of 
congenital skeletal disorders are based on genetic background, while others are named 
according to the anatomical position of the most predominant abnormalities seen in the 
skeleton1. For example, in spondylometaphyseal dysplasias the main radiographic 
abnormalities are found in the spine (spondylo) and the metaphyses of the long bones, 
acromesomelic dysplasias have short bones in the hands and feet (acromelic), and short 
middle parts of the limbs (mesomelic), while cleidocranial dysplasia is named after the 
abnormal clavicles (cleido) and cranium.  
 
Within the same nosology group there may be a significant overlap in the clinical presentation 
between different skeletal dysplasias.1 Genetic tests are therefore useful for differentiation, 
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because phenotypically overlapping conditions are often caused by pathogenic variants in 
genes coding for different molecules involved in the same cellular signalling pathway.  
 
The improvement in genetic diagnostics of skeletal disorders leads to a deeper knowledge 
about pathogenesis and allows accurate genetic counselling with information about 
recurrence risk in the affected family. Additionally, it may provide insights of the natural 
course of the disorder (learning from previously reported affected individuals) and potential 
complications that might be progressive or fatal if untreated. Family history may sometimes 
give clues to whether the skeletal dysplasia is caused by a de novo mutation or if it’s 
recessively inherited, but a precise molecular diagnosis is a prerequisite for the availability 
of future prenatal diagnosis and preimplantation genetic diagnosis (PGD). 
 
1.2 GENETICS 
In 1990, the road map to the human genome – the human genome project (HGP) – was 
initialized. It was an international research effort to sequence and localize all human genes,  
including protein domains and alternative isoforms. In 2001, the first draft of the human 
genome was released8,9 and in 2003 the project was announced completed.10 The main 
conclusion from this work was that the human genome contained much fewer genes than 
expected, with predictions pointing to between 60 000-120 000 genes. Today it’s estimated 
that the human genome contains about 3 billion nucleotides and approximately 20 000 protein 
coding genes. However, the current assembly of the human genome (GRCh37/hg19) still has 
gaps and certain genomic features, such as repetitive regions and pseudogenes, that remain 
problematic to study.10,11 
 
Organism complexity is not dependent on features such as genome size or number of genes 
in a species.12 However, alternative splicing, the mechanism when one gene produces more 
than one protein isoform and diversifies protein function is linked to human complexity. Most 
of the human genes (with more than one exon) undergo alternative splicing.13 Another 
important difference in organism complexity is the non-coding DNA, the functional elements 
that only produce RNA molecules. They are transcriptional regulating units, like microRNAs 
(miRNA) or long non-coding RNAs (lncRNA), that act as regulators, gene silencers or 
activators.14-16 The different range of post-transcriptional regulation, transcripts, and proteins 
in the cells and tissues – the transcriptome and proteome – are the links that decipher how 
our DNA leads a cell to normal development and function, or to a specific disease phenotype. 
 
In the last decade, there has been a great increase in the number of known disease genes and 
chromosomal aberrations in genetic diseases. The genetic diseases identified to date, are 
listed in the Mendelian Inheritance in Man (MIM) and accessible in the OMIM database, 
where over 15 500 genes and 7 800 clinical entities with known genetic causes are 
catalogued.17 Due to the diversity and phenotypic overlap among rare diseases, it is a 
challenge to diagnose patients with rare disorders solely based on phenotype. For extremely 
rare conditions, it is possible that a physician has never met a patient with that specific 
diagnosis before. Furthermore, the correct diagnosis may be difficult to pinpoint because of 
phenotypic variability. Today, there are many ongoing efforts (regional, national, and 
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international) to organize centres for patients to increase knowledge, experience, and research 
collaborations on rare diseases.  
 
The bioinformatic tools used to draft the human genome were also used to sequence the 
genomes of other organisms, such as mice and zebrafish. The results have been made publicly 
available allowing human genetic sequences to be compared to sequences of other organisms. 
Comparative genomics is of great importance since there are lots of conserved genes between 
organisms (i.e. orthologs) and if we can explain the function of a gene in a model organism, 
we might be able to deduct its function in humans leading to a broader understanding at the 
molecular level. Moreover, comparable genomics of organisms closely related to humans can 
give information about important features of DNA, like exons and regulatory elements (since 
they are more conserved).  
 
1.2.1 Genetic loci for skeletal dysplasias 
Most of the skeletal dysplasias are monogenic disorders and follow the pattern of monogenic 
inheritance: autosomal dominant, autosomal recessive, X-linked dominant, and X-linked 
recessive. In cases where the same phenotype can be caused by mutations in several genes or 
when the genetic aetiology is unknown, massively parallel sequencing (MPS) technologies 
using whole exome or whole genome sequencing (WES/WGS) is the golden standard to 
quickly achieve molecular diagnosis. Since WES and WGS provide many rare variants, 
correlation with the clinical and radiographic findings is essential for correct variant 
interpretation in skeletal dysplasias. 
 
The classification meetings for congenital skeletal disorders are held regularly in association 
to the International Skeletal Dysplasia Network meeting by a group of experts, who 
summarize the latest classification in a scientific report, updated every 4-5 year. In the last 
revision of the nosology and classification of genetic skeletal disorders from 2015 there are 
436 conditions, which are divided into 42 groups and caused by mutations in 364 genes.18 
The number of genes has increased dramatically since the previous revisions, from around 
80 in the 2001 classification19 to 226 reported disease-causing genes in the 2010 nosology 
report.20 The nosology could be seen as a “master list” of skeletal dysplasias or an overview 
of the different nosology groups, including genetic information. A clinical entity is placed in 
the nosology if it has been described in the literature and is included in a group because of 
similar pattern of skeletal involvement and/or a common genetic cause or molecular pathway. 
Before a gene is associated with a specific condition in the nosology, the genetic basis is 
proven in multiple patients and/or pathogenicity is confirmed with functional analyses.  
 
There are thousands of genes in which pathogenic variants are reported to cause monogenic 
diseases, but the genetic basis is still unknown for a significant number of rare diseases, 
including many skeletal dysplasias. This could be due to disease-causing genes that are not 
identified yet or genetic variants in known disease genes difficult to interpret or detect. Using 
current bioinformatic pipelines regulatory regions or other non-coding variants, such as 
synonymous variants and deep intronic variants that affect splicing, or middle-sized 
structural rearrangements are hard to find. Another scenario is digenic or oligogenic 
inheritance, when variants of two or more disease-causing loci segregate with disease. As an 
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example, triallelic inheritance have been reported by Katsanis et al. in Bardet-Biedl syndrome 
(BBS [MIM:209900]), which is when a combination of three pathogenic variants in two 
different genes are necessary to cause the disorder.21 There are also a few studies supporting 
digenic inheritance in BBS22 and it has been reported in skeletal ciliopathies once.23 On the 
other hand, a combination of all deleterious variants in an individual, the mutational load, 
might also explain incomplete penetrance, severity, and onset of disease.24 
 
1.2.1.1 Single gene defects 
To date, there are more than 450 genes associated with skeletal dysplasias, commonly 
included in smaller gene panels used for diagnosis. Using WGS or WES with panel-based 
filtering allows analysis of variants in the included genes. Over time, the in silico gene panels 
have been extended, with inclusion of new disease-causing genes and variants as they are 
reported. Furthermore, if a panel analysis fails to identify disease-causing variants, DNA 
samples of family members may be added for a trio/quattro molecular analysis. This approach 
may be necessary to achieve molecular diagnosis when the variants are in novel genes, not 
yet associated with a phenotype. 
 
Despite the genetic heterogeneity of skeletal dysplasias there are some with easy clinically 
recognizable phenotypes, such as cartilage hair hypoplasia, dyschondrosteosis, 
achondroplasia, pseudoachondroplasia, and hypochondroplasia. In these cases, the diagnosis 
is based on the clinical and radiological findings, and a single gene analysis. Molecular 
analysis is performed using conventional Sanger sequencing if the genes are small or there is 
a mutation hot-spot in the gene. For example achondroplasia is caused by a p.Gly380Arg 
substitution in the FGFR3 gene in 98% of the cases25 and the Finnish founder mutation in 
RMRP (c.70A>G) is very common in patients with cartilage hair hypoplasia (CHH 
[MIM:250250]) in northern Europe.26  
 
Even though some skeletal dysplasias are easy to diagnose, others are more variable with 
multiple phenotypes and genetic overlap, making Sanger sequencing laborious. For these 
entities, whole genome sequencing is more effective, allowing evaluation of both sequence 
and gene dose abnormalities. For example, at least 15 phenotypically different clinical 
skeletal entities caused by mutations in COL2A1 have been described so far. However, for 
most of them, radiographic features such as platyspondyly, “pear-like” vertebral bodies, and 
hypoplasia of the pubic bones are key radiographic features. Type II collagen is the major 
collagen synthesized by chondrocytes and the clinical variability and phenotypic overlap in 
these disorders are commonly observed, even within the same family.27  
 
In this thesis I have examined not only pure skeletal dysplasias but also skeletal syndromes, 
with internal malformations caused by metabolic and cilia abnormalities, therefore there is a 
need to introduce the congenital disorders of glycosylation (CDG) and the skeletal 
ciliopathies in the next two sections. 
 
  
 14 
Metabolic disorders with skeletal involvement 
Several metabolic diseases with a skeletal phenotype, have been described to date, such as 
mucopolysaccharidoses [MIM:607014] and congenital disorders of glycosylation (CDG). 
Mucopolysaccharidoses are a group of lysosomal storage disorders with a defect regulation 
of glycosaminoglycan (GAG) metabolism, that results in accumulation of GAGs in the cell 
and lead to a range of clinical features, including skeletal abnormalities with severe 
handicap.36 There are at least ten genes known to cause different forms of 
mucopolysaccharidoses. CDG is another group of metabolic disorders with either an 
autosomal recessive or X-linked inheritance and a vast number of clinical features. CDG 
patients show a wide range of biological abnormalities in protein glycosylation.37 
Glycosylation is a complex post-translational modification, attaching sugar to specific amino 
acids in many proteins (Figure 2), important in protein folding and transport.38 
 
In the majority of the cases, the disorder begins early in life and symptoms range from severe 
developmental delay and hypotonia with many organs involved, to milder symptoms. To 
date, there are more than 70 entities of the N-linked CDGs, but many of them have only been 
described a few times, limiting the phenotype-genotype correlation. The nomenclature for 
CDGs involve the gene name followed by CDG, for example ALG9-CDG. The consequences 
of an impaired glycosylation in skeletal dysplasias are not well-defined, but with more 
patients being reported with skeletal phenotypes in CDG, this diagnosis should be considered 
for unknown multisystem diseases, with symptoms including the skeleton.37 
 
Figure 2. Simplified scheme of the N-glycosylation pathway in the ER. The protein and LLO are generated 
separately and after subsequent enzymatic steps LLO is transferred into the luminal side of ER. Genes (in red 
letters) have been implicated in CDG. Severe skeletal changes have been reported in patients with pathogenic 
variants in ALG3, ALG9, and ALG12, which add mannose to the growing LLO. Mild skeletal changes 
(brachydactyly) have been reported in patients with disease-causing variants in ALG6 and ALG8, which add the 
first and second glucose. (Patients with ALG6-CDG and ALG8-CDG are also associated with many other 
features). In the end, the OST complex transfers LLO from the dolichol and attaches it to the asparagine residue 
on the protein in the ER lumen. Asn, asparagine; ER, endoplasmic reticulum; Glc, glucose; GlcNAc, N-
acetylglucosamine; LLO, lipid-linked oligosaccharide; OST, oligosaccharyltransferase. [This figure is modified 
from Ng BG et al.39 with permission from Elsevier] 
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Ciliopathies with major skeletal involvement 
Ciliopathies is a very broad group of genetic disorders caused by defective cilia functions. 
Within the skeletal ciliopathies there are multiple disease phenotypes with a phenotypic 
overlap and multiple disease-causing genes.28,29 Almost all cells in the body have cilia, which 
play an important role in organogenesis, cell migration, and signalling, including the skeleton 
formation. Ciliary proteins are synthesized in the cytoplasm and transported into the cilia in 
a process called intraflagellar transport (IFT). To date, pathogenic variants in at least 30 genes 
are known to cause skeletal ciliopathy phenotypes and all of them encode proteins either 
localized to the IFT machinery or is important for cilia structure and function.30 The cilia 
function as a signalling centre and are needed to maintain the cell organization in the growth 
plate and disruption of the cilia is thought to affect the Indian hedgehog (IHH) signalling 
pathway in skeletal ciliopathies.31 
 
The skeletal ciliopathies are classified according to their radiographic features and the most 
common clinical entities are short-rib polydactyly syndromes (SRPS) and asphyxiating 
thoracic dystrophies (ATD). In OMIM, they are grouped into a broader group of short-rib 
thoracic dysplasias (SRTD [MIM:208500]), Ellis-van Creveld syndrome (EVC 
[MIM:225500]), and Sensenbrenner syndrome (also known as cranioectodermal dysplasia; 
CED [MIM:218330]). The main characteristic skeletal features include narrow thorax, short 
tubular bones, metaphyseal flaring, hypoplastic lower part of the pelvis, and short hands with 
or without polydactyly. 
 
Deleterious variants in genes coding for proteins in the cilia compartments have similar 
effects on cilia function, leading to  phenotypically overlapping conditions, likewise 
mutations in the same gene can lead to other ciliopathy syndromes. For example, mutations 
in C2CD3 have been reported in both SRTD32 and Joubert syndrome (JBTS 
[MIM:213300]),33 both in combination with orofaciodigital syndrome (OFD [MIM:617127]) 
and mutations in CEP120 can lead to complex ciliopathy phenotypes34 and SRTD.35  
 
1.2.1.2 Chromosomal aberrations 
Larger chromosomal aberrations include deletions, tandem duplications, inversions, 
insertions, and translocations (Figure 3), comprising of only a few exons of a disease-causing 
gene to a whole chromosome. Deletions and duplications are copy number variants (CNV) 
with loss or gain of genetic material, compared to the reference genome. The size cut off for 
a CNV stretches >50 base pairs within the genome, although the size is arbitrary and depends 
on technology limitations.40 Most of the skeletal dysplasias are monogenic disorders caused 
by small changes and only a few are caused by recurrent rearrangements (larger duplications 
or deletions). SHOX haploinsufficiency, including recurrent deletions and CNVs in flanking 
regulatory elements is one of the well-known examples.41,42 Any chromosomal aberration 
involving a gene important for skeletal development will most probably lead to skeletal 
abnormalities and additional features depending on whether other genes are affected by 
haploinsufficiency. For example, such as in the 1q24q25 deletion syndrome, comprising of 
at least thirteen genes, where affected individuals have learning disabilities and distinctive 
facial characteristics, in addition to short stature and brachydactyly.43 
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Figure 3. Schematic overview of large structural variants showing chromosomal abnormalities on 
chromosome 4 and 20. Even though inversions, insertions, and balanced translocations do not lead to loss 
(deletion) or gain (duplication) of genetic material, these events can result in gene disruption and phenotypic 
consequences. [Courtesy of National Human Genome Research Institute and the Smithsonian National Museum 
of Natural History] 
 
 
 
 
 
Figure 4. Gene expression regulation within TAD domains and effect of structural variants. A. Healthy 
genome with two TADs that separate inactive gene A from the regulatory element and expressed gene B. B. 
Deletion of a TAD boundary causes a fusion of the two TADs and the regulatory element can also activate gene 
A. C. Duplication within the TAD (intra-TAD) making two copies of gene B. D. Duplication involving the TAD 
boundary between two TADs (inter-TAD) and a regulatory element from neighbouring TAD activates gene A in 
the new TAD (neo-TAD). E. Inversion containing the TAD boundary and regulatory element enable activation of 
gene A. The TAD containing gene B lost its regulatory element and gene B is repressed. Dashed line indicates 
the genomic structural variant. TAD, topologically associated domain. 
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It is known that structural variants or rearrangements outside the coding region can impact 
gene expression if they affect promoters or enhancers of disease genes. In recent years, 
studies using conformation capture technologies show the 3D-organization of the genome 
and describe topologically associating domains (TADs) to be responsible. TADs are 
important to promote the contact within a domain (promoter and/or enhancer will physically 
be close to the gene), but there is very little contact between different TADs. It is now clear 
that altering a TAD boundary can have impact on gene expression, because regulatory 
elements within TADs can affect gene expression and in some cases result in disease (Figure 
4).44,45 In mouse, the Shh region have been extensively studied for how TADs are responsible 
for the anterior-posterior positioning of the limb bud. It has been shown that disruption of the 
TAD boundaries alter the communication between Shh and its regulatory element and cause 
truncation of the limbs, while deletions within the TAD have no impact of limb formation.46 
In humans, preaxial polydactyly have been shown in individuals with duplication spanning 
the regulatory element of SHH.47  
 
1.2.1.3 Imprinting defects with skeletal abnormalities 
Genetic imprinting means that different genes are expressed dependent on parent-of-origin 
of the methylated regions and it is known to be important for normal development. There are 
very few syndromes with skeletal symptoms associated with imprinting abnormalities. Some 
imprinting defects are classified as differential diagnoses to skeletal dysplasias, while others 
are included in the nosology of skeletal dysplasias.1 One imprinting defect with skeletal 
features is the Kagami-Ogata syndrome (KOS14 [MIM:608149]) that is caused by either a 
maternally inherited microdeletion of a differentially methylated region (DMR) on 
chromosome 14q32.2 or by paternal uniparental disomy of chromosome 14 (UPD14). 
Opposite to paternal UPD14, maternal UPD14 is known as Temple syndrome (TS14 
[MIM:616222]) with short stature, intellectual disability, and early onset of puberty.48 A 
differential diagnosis to TS14 is Silver Russel syndrome (SRS [MIM:180860]) caused 
mainly by loss of methylation of chromosome 11p15 or maternal UPD7.  Other examples 
include pseudohypoparathyroidism Ia (PHP1A) and pseudopseudohypoparathyroidism 
(PPHP), both presenting with a phenotype of Albright hereditary osteodystrophy with or 
without hormone resistance respectively, and both are caused by mutations in the GNAS 
locus.49 
 
1.2.1.4 Non-coding RNAs 
Even though, most of the disease-causing variants reside within a protein coding gene, some 
studies suggest a role for non-coding RNAs in skeletal dysplasias and syndromes.16 CHH is 
a skeletal dysplasia that is relatively common in Finland, with symptoms including short 
stature, a high risk for cancer, and immune disorders. The responsible gene was found in 
2001, RMRP, a gene not coding for a protein, but an RNA molecule important for 
mitochondrial transcription and replication.26 
 
There is a large group of small non-coding RNAs, the microRNAs (miRNAs), regulating 
gene expression. They have shown to target a vast amount of human genes and many of the 
miRNAs lie within genes both in introns and exons. Many of the miRNAs regulate key 
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proteins in skeletal development and depending on target they regulate gene expression by 
selectively silencing them. One miRNA can target several hundred genes and one gene can 
have different binding sites for more than one miRNA, making this to a complex network of 
gene regulation, which is often tissue specific.16 There have not been many cases reported 
with skeletal symptoms in humans that are caused by disruption of a miRNA, but one 
example is the deletion of a miRNA cluster (miR-17~92) that causes brachydactyly, 
scaphocephaly, and short stature.50 With the increase of studies performed on miRNA, the 
list of miRNAs causing diseases will most likely increase in the future.  
 
1.2.2 Interpretation of variants 
The diagnostic yield for skeletal dysplasias using MPS based panels and exomes is around 
60%,51-56 but seems to depend on skeletal phenotype in the cohorts. Studies including a broad 
range of skeletal dysplasia patients with many genes have lower outcome, while more defined 
cohorts like osteogenesis imperfecta or skeletal ciliopathies have been reported with genetic 
diagnoses in more than 80% of the cases.52,55 There is a great challenge in interpreting the 
identified variants, when a single individual may harbour millions of variants and only one 
or a few are disease-causing. The rest of the variants account for normal variation.  
 
A single nucleotide variant (SNV) refers to that one nucleotide is replaced by another one, 
sometimes also referred to single nucleotide polymorphism (SNP). However, SNV is 
favoured over SNP, since a polymorphism implies that it is a common variant with a 
frequency of at least 1% in a population. Each individual is predicted to carry at least three 
million SNVs and around 1 000 CNVs, which means that the genetic variation between two 
individuals differ roughly about 0.1% due to SNVs and 1% due to CNVs.57 The genetic 
diversity differs between populations and it have been shown that African populations have 
more genetic variations compared to other populations outside Africa. This seem to match 
the out-of-Africa hypothesis which resulted in a population bottleneck and loss of genetic 
diversity.58 
 
To improve the variant analysis, the concept of minor allele frequency (MAF) was 
introduced. It defines the frequency of a variant (the less common allele) at a certain position 
in the genome in a population. The allele frequency of a SNV differ between populations and 
ethnical groups as well as for certain diseases. This is important to have in mind when 
interpreting a variant, because a variant that is rare in one population could be common in 
another and should not be considered as pathogenic, and the incidence of a disease is 
dependent on MAF. The 1000G project, SweGen, ExAC, and gnomAD consortium have 
made databases available with more than 120 000 exomes and genomes,59-61 with the 
invaluable landscape of human genetic variation needed to filter MPS data. The SweGen data 
set comprise of 1 000 individuals from the Swedish population and is a valuable source for 
local genetic variation and since many of our samples are run on the same platform, detecting 
sequencing errors as possible pathogenic variants are minimized.60 
 
There are different types of SNVs in the DNA code: missense, silent, frameshift, and protein-
truncating variants (PTVs). PTVs include introduction of a stop codon (nonsense) and splice 
variants caused by SNVs. The missense variants are the most common and could easily be 
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checked for conservation across species using SIFT (Sorts Intolerant From Tolerant)62, 
PolyPhen2 (Polymorphism Phenotyping version 2),63 and GERP++,64 but for nonsense, 
synonymous, and PTVs these prediction tools are poor. Combined Annotation Dependent 
Depletion (CADD) is another tool that measures the deleteriousness for all variants across 
the genome and integrates multiple annotation tools into a C-score for interpretation.65 This 
value is useful in prioritizing all disease-causing variants. 
 
The deleterious alleles tend to be rare and population allele frequency from ExAC have been 
used in attempt to identify genes with a high probability of loss-of-function intolerance metric 
score (pLI >0.9).59 This is applicable for PTVs and genes that cause dominant disorders, 
while the constraint metric gives Z-scores for CNVs, synonymous, and missense variants. 
Positive Z-scores suggest an intolerance to variation in the gene and if the Z-score is >3.09 
there is less observed variants than expected, while negative Z-scores have more variations 
than expected and are tolerant to variation.59 Interpretation of variants can therefore be guided 
by the use of constraint scores. 
 
Many variants are extremely rare and have just recently been introduced in the coding 
sequence, thus only shared by close relatives or cluster in a population. De novo variants 
occur in each generation with an incidence of 1.0-1.8 every 108 nucleotides per generation. 
Each individual carries around 50 to 70 SNVs and less than ten smaller indels (<50 bp) in the 
genome, that neither of their parents have.66,67 One or two of these SNVs affects the coding 
region, but is not necessarily causing disease. Therefore, the pathogenicity of a variant cannot 
solely be based on if the variant is de novo or not. Another limitation is the functional impact 
of the variant that can be hard to predict. One variant might lead to a complete or partial loss-
of-function (LOF, so called inactivating variants), reducing the proteins normal function. 
Other variants may lead to activation of the protein (so called gain-of-function variants, 
GOF), that either lead to a stronger activation of the protein function or a totally new function 
(neomorph). The distinction between these different forms of variants are usually only clear 
when performing functional studies. 
 
In summary, after filtering for a variant using gene, amino acid, and nucleotide conservation, 
constraint metrics, allele frequency, and inheritance pattern, as well as previous reports in 
disease-variant databases (i.e. HGMD, ClinVar, DECIPHER) the amount of deleterious 
variants will decrease significantly. Hopefully, there are only a few left to interpret further 
for clinical relevance and disease mechanism. Using the American College of Medical 
Genetics and Genomics (ACMG) variant classification system the remaining variants may 
be placed into one of five categories (benign, likely benign, variants of unknown significance 
(VUS), likely pathogenic, and pathogenic).68 After whole exome or genome sequencing 
without filtering for a gene panel many variants will fall into the VUS category. Finally, it is 
important to remember that variants that have been reported previously as pathogenic, may 
actually be benign and vice versa.69,70 
 
Currently, due to the insufficient understanding of non-coding variants, their interpretation 
is not as accurate as the coding variants. In fact, despite the knowledge available on non-
coding regions, most variants that are considered are located within protein-coding genes.71 
 
 20 
1.2.2.1 Splice variants 
Pre-mRNA splicing is mediated by the spliceosome, a large complex of proteins, that 
recognizes the canonical splice sites at the acceptor and donor splice site, the branchpoint, 
the polypyrimidine tract, and other recognition sites (Figure 5A).72 The spliceosome consists 
of five small nuclear ribonucleoproteins (snRPs) and is dependent on hundreds of splicing 
factors that are usually expressed in cell-type specific fashion. During transcription, an 
organized series of events lead to the cleavage of phosphodiester bonds at the exon-intron 
boundaries and the exons are ligated, whereas the introns are removed. The awareness that 
disease-causing variants may affect regulatory elements in splicing have led to a different 
approach in evaluating possible splice variants, though they are difficult to interpret73 and 
most likely underestimated. Correct interpretation of splice variants will most likely increase 
diagnostic yields.  
 
Several studies show that up to 10% of reported missense and synonymous variants actually 
affect pre-mRNA splicing.72,74 SNVs can be located within and outside of the coding exons 
of a gene and still can have an effect on splicing and protein expression. The spliceosome 
binds to recognition sites to regulate splicing, which can be both exonic and intronic. These 
regulatory elements can work as either splicing silencers or enhancers.75 Disease-causing 
splice variants most often occur at the exon-intron boundary, ±2 base pairs from the canonical 
splice site and usually lead to exon skipping, but there are also deep intronic splice variants 
that lead to exon inclusion.76 Other variants may introduce a cryptic splice site in close 
proximity to the existing splice site, causing partial retention of intronic sequence within the 
transcript, deletion of the exonic sequence upstream of donor splice site or retention of the 
whole intron in the mRNA (Figure 5B). 
 
Canonical and non-canonical splice variants can lead to both LOF and GOF mutations. The 
functional effects of these mutations depend on which gene and position of the variants and 
if they lead to in-frame or out-of-frame translation, as well as if nonsense mediated decay 
(NMD) occurs or not.77 
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Figure 5. Classical splicing signals for U2 and U12-dependent human introns with regulatory elements (A) and 
modes of alternative splicing (B). A. Consensus sequences of splice recognition sites, where the letter size 
corresponds to its frequency at each position. The U2- and U12-dependent introns differ by their dinucleotide 
composition at the canonical splice site and branchsite motif. In many introns upstream of the 3’ splice site there 
is a polypyrimidine tract (usually represented by cytosine or thymine) and a branchsite 20-50 base pairs upstream 
of the polyPy. Additional regulatory elements in the exons or introns are recognized by the splicing machinery 
for correct splicing to occur (exemplified as red or green bars). B. Four common modes of alternative splicing 
that can occur and lead to different outcomes. Dashed lines indicate splicing options. ESE, exonic splicing 
enhancer; ESS, exonic splicing silencer; ISE, intronic splicing enhancer; ISS, intronic splicing silencer; polyPy, 
polypyrimidine tract; ss, splice site. [Permission obtained from Elsevier to reuse parts of figure 1 from Padgett et 
al.72] 
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1.2.3 Reverse phenotyping 
Clinical diagnosis of a skeletal dysplasia is many times established by an experienced 
radiologist, geneticists or paediatrician based on pattern recognition. However, if a patient 
has an atypical phenotype, reverse phenotyping can be used, analysing the genetic data first 
and correlating the clinical findings next. In some cases, the clinical diagnosis can be revised 
after genetic testing or it may lead to the identification of a novel gene behind the atypical 
phenotypes. There is a small proportion of patients who are affected by more than one genetic 
condition,78,79 this is mainly true for consanguineous families80 and it should be addressed 
when expanding the phenotypic spectrum of a known condition, including skeletal 
dysplasias. 
 
1.2.4 Phenocopies of skeletal dysplasias 
There are a number of factors that may lead to conditions, mimicking skeletal dysplasias, that 
are not caused by genetic factors. Internal and external factors, including nutritional 
deficiencies (for example insufficiency of vitamin D), maternal infections (for example 
Rubella and Zika virus), unrelated pharmacological treatments that influence skeletal 
development (such as prenatal exposure to warfarin), and maternal autoimmune diseases with 
autoantibodies crossing the placenta during pregnancy (such as systemic lupus 
erythematosus, mixed connective tissue disorder, and Sjögren syndrome).81 Therefore an 
adequate disease history is necessary in order to obtain the correct diagnosis.  
 
1.3 NORMAL AND ABNORMAL DEVELOPMENT OF THE SKELETON 
There are 206 bones in the human skeleton that function as a structural framework for the 
body and protect the inner organs. The skeleton also facilitates movement and has a metabolic 
role as a supply of minerals, cytokines, and growth factors needed for its modelling. The 
skeleton is formed at the embryonic stage and the growth of bones continues to the mid-
twenties. In order to retain the skeleton, the bone mass is preserved in adult life through the 
action of bone formation and bone resorption.82 Different signalling pathways define how the 
bone forms and how it is shaped into the right size and orientation.  
 
1.3.1 Bone formation 
The process of bone formation in the embryo is initiated by mesenchymal stem cells (MSC, 
mesoderm and neural crest cells), following condensation and differentiation. There are two 
main processes of how bone is built; endochondral and intramembranous ossification. The 
long tubular bones are built through the process of endochondral ossification, whereas the 
flat bones are built by intramembranous ossification.83 Numerous genes control bone 
formation and metabolism, and recognition of signalling pathways responsible for disease 
provides us with insight on how the molecular mechanisms work in normal development. 
 
1.3.1.1 Endochondral ossification 
In endochondral ossification, in the early embryo, the differentiation of the MSC into 
chondrocytes is dependent on SOX transcription factors and bone morphogenetic protein 
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(BMP) receptors. SOX9 is crucial for this process shown by mutations in SOX9 resulting in 
campomelic dysplasia (CMDP [MIM:608160]), often a semilethal disease with bowed 
femora and small thoracic cage.84 
 
In cartilaginous bones, the anlagen is formed from condensed MSC and ossification begins 
in the central part of it in the primary ossification centre, which gradually forms the diaphysis. 
Later, at the end of the cartilaginous anlagen, secondary ossification centres develop and 
establish the epiphyses, which are located in the proximal and distal parts of the long bones. 
The cartilage layer between the primary and secondary ossification centres is called the 
epiphyseal growth plate (Figure 6). 
 
In the growth plate, the chondrocytes grow towards the metaphysis, forming columns and are 
divided into four zones; resting, proliferative, hypertrophic, and mineralization zone. The 
resting chondrocytes serve as a supply of stem cells. When the stem cells divide, they form 
well-defined columns of chondrocytes, defining the proliferative zone, which synthesize 
collagen type II, aggrecan, and fibroblast growth factors (FGFs). In the hypertrophic zone, 
the cells increase their volume and produce more extracellular matrix which calcifies. The 
matrix is invaded with vessels and osteoblasts which will form the mature trabecular bone.83 
The perichondrium is a layer of connective tissue that surrounds the cartilage of developing 
bones important for growth regulation. Growth plates are fused in the end of puberty, which 
in case of skeletal dysplasia leads to a less specific radiographic appearance of the bone and 
the diagnostic signs diminish or disappear.83,85 
 
 
Figure 6. Schematic representation of the growing long bone. The epiphyseal growth plate from proximal 
tibia of mouse is stained by safranin and fast green. The growth plate can be divided into four zones; resting, 
proliferative, hypertrophic, and mineralization zone.  
 
 
Cell proliferation and differentiation in the growth plate is a complex process and is tightly 
regulated by hundreds of genes, among them SOX9, FGFR3, IHH, PTHLH, COL2A1, 
COL10A1, and RUNX2.83 Mutations in these genes cause different types of skeletal 
dysplasias. Indian hedgehog (IHH) plays an important role in the regulation in endochondral 
ossification. It is expressed in the prehypertrophic and hypertrophic chondrocytes in the 
growth plate and participates in a negative feedback loop involving parathyroid hormone 
related protein (PTHrP, encoded by the PTHLH gene), coordinating chondrocyte 
proliferation and hypertrophy. IHH induces PTHrP production in the articular end of the long 
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bones and PTHrP maintains the chondrocytes in proliferative state and delay the transfer to 
prehypertrophic chondrocytes by binding to its receptor, PTHR1.86 In agreement with this 
mechanism, activating mutations in PTHR1 cause autosomal dominant metaphyseal 
chondrodysplasia type Jansen [MIM:156400], resulting in impaired chondrocyte 
proliferation and therefore a widened growth plate.87 On the other hand, inactivating 
mutations cause autosomal recessive Blomstrand chondrodysplasia (BOCD [MIM:215045]), 
a lethal condition characterized by severely advanced skeletal maturation, increased bone 
density, and severe midface hypoplasia.88 Heterozygous mutations in IHH and PTHLH lead 
to short stature and brachydactyly,89,90 while homozygous or compound heterozygous 
mutations in IHH have been reported to cause a more severe phenotype of acrocapitofemoral 
dysplasia (ACFD [MIM:607778]).91  
 
During the maturation of bone, the hypertrophic chondrocytes secrete extracellular matrix, 
mostly composed of collagens and minerals, a process regulated by RUNX2, important for 
the formation of the periosteum and osteoblast differentiation.92 RUNX2 regulates type X 
collagen expression, responsible for the deposition of extracellular matrix. Mutations in 
COL10A1 are associated with autosomal dominant Schmid type metaphyseal 
chondrodysplasia (MCDS [MIM:156500]) and lead to altered chondrocyte differentiation.93 
 
The fibroblast growth factors (FGFs) regulate many functions of the skeleton, including 
embryonic development, cell growth, and migration and are very important during epiphyseal 
growth plate formation. The complexity and diverse functions of FGFs is exemplified by the 
wide range of congenital disorders observed when the pathway is disturbed. A member of 
this family is FGFR3, where activating mutations in the gene give rise to a spectrum of 
phenotypes from mild to severe conditions, including hypochondroplasia (HCH 
[MIM:146000]), achondroplasia (ACH [MIM:100800]), severe achondroplasia with 
development delay and acanthosis nigricans (SADDAN [MIM:616482]), and thanatophoric 
dysplasia (TD1 [MIM:187600]; TD2 [MIM 187601]). The severity of the phenotype 
correlates with the degree of the receptor activation. A strong FGFR3 activation inhibits 
chondrocyte proliferation, hypertrophy, and increases mineralization to a more severe degree 
in TD1, TD2, and SADDAN, while moderate FGFR3 activation leads to milder abnormalities 
in the growth plate in ACH and HCH.94 In contrast, inactivating mutations in FGFR3 cause 
tall stature with arachnodactyly.95 
 
1.3.1.2 Intramembranous ossification 
In the intramembranous ossification the flat bones (the skull, clavicle, and lower jaw) are 
formed without chondrocytes as precursors. Ossification is initiated by mesenchymal stem 
cells (cranial neural crest cells) that form a scaffold where the cells differentiate directly into 
bone-forming cells, the osteoblasts. The osteoblasts produce type I collagen and osteoid 
matrix and mineralize. The process is initiated by the transcription factors RUNX2 and its 
downstream target SP7 (Osterix), both proteins important in both intramembranous and 
endochondral ossification.96,97  
 
Heterozygous mutations in the Runt-related transcription factor 2 (RUNX2), which is 
required for osteoblast and chondrocyte differentiation, results in cleidocranial dysplasia 
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(CCD [MIM:119600]), a skeletal dysplasia with insufficient membranous ossification of the 
skull and clavicles.92,98 Complete loss of RUNX2 leads to poor calcification of bone in mice,99 
but in humans homozygous LOF variants in RUNX2 have not been described. Other 
transcriptional factors important for appositional growth of the flat bones are MSX2 and 
TWIST, and mutations in both genes are known to cause craniosynostosis.100,101 
 
1.3.2 Bone remodelling 
Bone remodelling is the process by which the old bone is resorbed by osteoclasts (bone 
resorption) and new bone is produced by osteoblasts (bone formation). This activity is 
rigorously regulated to retain a healthy skeleton and an imbalance between these two features 
lead to skeletal dysplasias characterized by increased or decreased bone mineral density 
(BMD). Impaired bone resorption is dependent on the activity of the osteoclasts and its 
secretion of enzymes important for resorption. It is highly regulated by calcium levels, low 
levels of calcium in blood prompt secretion of parathyroid hormone (PTH), which increases 
the activity of the osteoclasts and release of calcium from skeletal tissues. In opposite, high 
levels of calcium stimulate secretion of calcitonin which inhibits the activity of osteoclasts 
and leads to decreased bone resorption. A large number of cytokines and growth factors, such 
as oestrogen, growth hormones, and glucocorticoids are known to regulate bone 
remodeling.102 Acquired abnormalities of the above mentioned hormones influence skeletal 
metabolism, often leading to secondarily decreased BMD. Primary congenital disorders with 
symptoms of impaired bone homeostasis are for example osteogenesis imperfecta (OI) and 
different types of osteopetroses. 
 
OI is characterized by brittle bones and is inherited in a recessive or dominant manner and 
occurs when type I collagen genes or genes responsible for synthesis of type I collagen or its 
posttranslational modification are mutated. OI patients’ bones are characterized by low BMD 
that easily break, leading to multiple fractures. Glycine mutations in COL1A1 and COL1A2 
are the most common reason for OI, and these mutations act dominant negatively, disrupting 
the triple helix, and folding of the collagen.55 While the bones are less dense in OI, 
osteopetroses have an increased BMD due to defective bone resorption, but in both diseases 
the bone is fragile and breaks easily. The molecular causes for osteopetroses are either 
mutations in genes essential for osteoclast differentiation in the RANKL signalling pathway 
or in genes essential for the acidification of the extracellular compartment, which disrupts 
the osteoclast function and leads to impaired bone resorption.103 One example being CLCN7, 
that encodes a membrane protein responsible for the increase of chloride concentration within 
the lysosomes, thus an important player for the acidification. 
 
In conclusion, there are many proteins and RNAs involved in the complex regulatory 
pathways important for skeletal development and homeostasis. If any of these processes are 
affected by a genetic abnormality, they can result in a congenital skeletal condition. 
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2 RESEARCH APPROACH 
2.1 AIMS 
The overall aim of this thesis was to expand the genetic and phenotypic spectrum of skeletal 
dysplasias in order understand the molecular background of some selected clinical entities 
and to improve diagnostic rate for skeletal dysplasia patients using WES and WGS. The 
specific aims addressed in this thesis were as follows: 
 
I. To summarize clinical, radiographic, and genetic features of previously recognized 
skeletal dysplasias in order to obtain data on natural course and phenotypic spectrum 
of the conditions.  
II. To identify novel clinical and genetic entities among the skeletal dysplasias and to 
understand their associated molecular pathology. 
 
2.2 PATIENTS 
In study I-V patients were referred to Department of Clinical Genetics, Karolinska 
University laboratory, Karolinska University Hospital because of a suspected congenital 
skeletal dysplasia. Informed consent was obtained from all affected patients or their 
parents/legal guardians and the studies were approved by the ethical review board at 
Karolinska Institutet. Thorough medical history, including skeletal features and symptoms, 
orthopaedic surgeries, extra-skeletal manifestations, medications, and anthropometry data 
were collected from hospital records. Skeletal surveys were reviewed at least by two experts 
within clinical skeletal dysplasia diagnostics. In study III-V patients were also referred to us 
from collaborating groups and included in the studies because they presented with the same 
clinical features. In all studies, clinical assessment and interviews of the affected patients 
and/or their families were performed. 
 
2.3 METHODS 
This section describes the methods used in the studies to generate data for interpretation of 
the congenital skeletal dysplasias.  
 
In the past, loci for monogenic disorders were found with linkage markers and many of the 
mutated genes behind skeletal dysplasias were mapped with this or similar techniques.18,20 
The main techniques used in the clinic today are Sanger sequencing, multiplex ligation-
dependent probe amplification (MLPA), and array-comparative genomic hybridization 
(aCGH). Sanger sequencing depends on PCR amplification of regions of interest, and in the 
end will resolve the order of nucleotides in the DNA sample to be compared to a reference 
sequence. MLPA and aCGH detect CNVs with a resolution depending on where the probes 
are located, but generally smaller deletions and duplications are not found.  
 
Currently, exome and genome sequencing have successfully been implemented in the 
diagnostics of rare heterogeneous diseases, including skeletal dysplasias. The real power of 
this technology is forthcoming, but using whole genome sequencing data is of great 
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importance to find CNVs, and structural abnormalities such as inversions and translocations, 
in addition to SNVs and smaller deletions and duplications, that otherwise would be missed. 
 
2.3.1 General outline of the studies 
Individuals without known genetic cause for their skeletal conditions were included in 
subsequent studies aiming to identify causative gene defects. The collected DNA samples 
were analysed with WES or WGS and in selected cases with aCGH to detect or confirm gene 
dose imbalances. Disease-causing and candidate variants were verified using Sanger 
sequencing or MLPA. The applied methodology was decided on a case-by-case basis, a 
typical flow chart of the study can be seen in Figure 7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7. Flow chart of study - from patient with a skeletal dysplasia to molecular diagnosis. Many 
times, a joint international collaboration is needed to find more than one patient with the same rare disorder 
and functional studies have to be performed to confirm pathogenicity of the detected novel variants. CNV, copy 
number variation; SKD, skeletal dysplasia; WGS, whole genome sequencing.  
 
2.3.2 Whole genome and exome sequencing 
In brief, WES and WGS allow massive parallel sequencing simultaneously.104-106 First, the 
DNA is fragmentated randomly into short segments (around 300-500 base pairs and 
organized into libraries. Second, adaptor sequences are ligated to both ends of the fragments 
and the adaptors bind to an array that allows the single-stranded DNA to be physically 
separated. In some applications each DNA segment is then amplified by PCR, or directly 
undergoes cyclic array sequencing – where primers bind to the adaptor sequences and 
sequencing starts. Each nucleotide carries a fluorescent label and is read directly when bound 
to the DNA. Both ends of the DNA are sequenced giving “paired end” (PE) reads where the 
number of bases between the ends is known (both reads map within a short distance). In 
 
Patients with a well-defined skeletal 
phenotype with unknown genetic 
etiology 
WES, WGS and CNV analyses 
Analyze previously known skeletal 
dysplasia genes and prioritize variants 
Mutations in known SKD genes Unsolved genetic etiology 
Correlation to the clinical 
information and report  
WGS and CNV analyses in 
family trios 
Evaluation of candidate 
gene/variant 
Matchmaker exchange and/or 
joint collaboration effort 
 
Clinical report 
 
Functional studies 
 
  29 
contrast, the mate pair sequencing (MP) has longer inserts, 2-20 kbp with PE-reads, but since 
a pair of inserts have a larger distance they are more suitable to read through repetitive 
sequences and sequences with structural rearrangements. The consensus in the field is to have 
a mean coverage at 30-40 times [30-40X], which reduces the error rate and reveal 
heterozygous variants. 30X mean coverage will cover 99.96% of the reference genome, but 
only 95% will be covered more than 8X.106 
 
The sequences are subsequently aligned to the human reference genome with overlapping 
reads, followed by variant calling. Since WGS identifies within 3.4 to 5.3 million variants in 
an individual’s genome compared to the reference, bioinformatic tools are essential. To filter 
the variants based on phenotype, segregation analysis, and/or online databases reduce the 
number of candidate variants. Another way to reduce the target region could be to only 
sequence the coding parts – exome sequencing – covering around 1.5% of the genome. This 
yields roughly 25 000 genetic variants107 and reduces the amount of data and time needed to 
analyse the data. While WES is suited to identify monogenic disorders, it cannot be used to 
find breakpoints for structural rearrangements and the first exon usually has a lower coverage 
due to its high GC content, and does not target non-coding regions. WGS provides a more 
homogeneous coverage of the whole genome data, is more efficient and can be used to find 
not only single or few nucleotide variants, but also structural and gene dose abnormalities.108 
Figure 8 shows one example of how WGS data finds a 5 kb deletion of FOXC1 in a patient 
just by looking at the coverage.  
 
 
 
Figure 8. WGS data in proximity to FOXC1, showing the deletion breakpoints on chromosome 6p of a 
patient with a skeletal syndrome. There is only loss of one copy of FOXC1 and no other genes are involved. 
This deletion was confirmed by aCGH. [Courtesy of Grigelioniene G and Garza-Flores A, unpublished data] 
 
The interpretation of genomic variants is challenging, but the workflow to confirm the 
causality of the variants is:  
 
I. Segregation analysis in the family. 
II. Identification of the same disease-causing variant or other pathogenic variants in the 
same gene, in unrelated individuals with the same phenotype (using literature reports, 
DECIPHER, HGMD, ClinVar, and/or Matchmaker exchange). 
III. Information of frequency of variants in our in-house database and online databases, 
such as gnomAD, ExAC, 1000G, and SweGen. 
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IV. Prediction tools of the conservation and functional effect of the variants, such as 
CADD, GERP, SIFT, Polyphen-2, ESEfinder, and different splice prediction tools. 
 
The segregation analysis of a variant is usually done with Sanger sequencing of parental 
samples and in some cases also of other family members. Segregation analysis is used to 
examine if variants are following with the inheritance pattern of the studied condition in the 
family or if they are de novo. When analysing X-linked recessive disorders, it is important to 
discern whether the mother is a heterozygous carrier and if there are any other female 
members in the family that might be at risk of carrying the disease. For a VUS on the X 
chromosome it is useful to see if the variant can be found in hemizygous state in a healthy 
male relative or not. For novel variants in genes previously not known to be involved in 
disease, functional studies are necessary to confirm the pathogenicity. 
 
2.3.3 Copy number variant analysis 
MLPA and aCGH are normally used when a gene dose imbalance of a gene or region is 
suspected. With MLPA, a multiplex PCR is used that allow amplification of multiple targets 
in one reaction. Separating the fragments by size in each individual gives a ratio between 
patient and reference (healthy individual) indicating a deletion (<0.75) or a duplication 
(>1.25). Specific modifications of MLPA can also be used for analysis of DNA methylation 
and single nucleotide variations.109 For aCGH, gene dose imbalances are found with 
differentially labelled DNA of a patient and a reference sample that are hybridized to an array 
with probes. A dosage change is found when the ratio of patient and reference fluorescent 
signals are unequal. It is possible to run custom designed arrays, which means that areas are 
selected on the array slide to cover regions associated with disease, an approach which is 
combined with probes distributed evenly over the genome (used in this study). Another 
approach for aCGH is SNP arrays that will find loss of heterozygosity (LOH) in addition to 
gene dose imbalances.110 
 
To confirm the exact breakpoints of a deletion, a break-point PCR can be designed to amplify 
the region of interest, with amplification only possible when the break-point is present in the 
DNA sample. A break-point PCR can also be used for inversions and translocations, but since 
they are not CNVs, they will not be found with MLPA or aCGH, but are possible to detect 
with WGS. 
 
2.3.4 cDNA analysis of predicted splice variants 
The molecular diagnoses were confirmed in a total of six families (in study I and V) by 
analysing cDNA from the affected patients or their parents. The variants were suspected to 
affect splicing, either in close proximity (+2 base pairs from the exon-intron boundary) 
(study I) or further away (9 and 16 bases upstream of canonical splice site) (study V). 
Furthermore, two synonymous variants in KIAA0753 and DYNC2H1, respectively, were 
thought to introduce exon skipping (study V). Primers were designed for the coding region 
close to the variants in ALG9, DYNC2H1, EVC, and KIAA0753 (one of the primers usually 
spanning over two exons to reduce amplified genomic DNA) and subsequent Sanger 
sequencing was performed to show the aberrant splicing. 
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2.3.5 Histology and immunohistochemistry of the growth plate 
Growth plate studies are usually only possible in animal models and in fetuses from 
terminated pregnancies. These samples can be used to observe structural abnormalities of the 
growth plate and to examine expression of RNA or proteins of interest. In study IV paraffin-
embedded sections of the distal femoral growth plate from the affected fetus was stained with 
haematoxylin-eosin and compared to an age-matched control fetus. Further, 
immunohistochemistry with antigen retrieval was performed in citrate buffer and after 
blocking the slides they were incubated with primary antibody to KIAA0753 and GAPDH, 
secondary fluorescent antibody and nucleus was counterstained with DAPI. Images from the 
microscopy were analysed using ImageJ software.  
 
2.3.6 Zebrafish as a disease model  
In order to verify the disease-causing effect and to study the pathophysiology of a specific 
skeletal dysplasia gene, we can use model organisms. This is possible since many genes are 
conserved between species and their proteins have similar functions. Zebrafish are 
particularly suitable for early developmental studies, because of its external fertilisation and 
development (compared to in utero in mice). We can therefore, follow the embryonic 
development using a dissection microscope. Other advantages of using zebrafish in genetic 
studies include the large collection of mutant and transgenic lines and the molecular tools 
available to knock-down or overexpress genes of interest. Tissues and organs from zebrafish 
and humans are in general comparable, especially at the cellular level, and therefore zebrafish 
can be used to understand specific pathways and mechanisms, including cilia biogenesis. 
Although, some molecular mechanisms may be different between them similar phenotypes 
have been observed in zebrafish when knocking out disease genes and give a model that 
resembles ciliopathies in humans.111 By comparing wildtype and mutant zebrafish, we can 
describe the role of any gene of interest, its role in disease, and test compounds with 
therapeutic potential. 
 
In study IV zebrafish was used as a model organism to confirm the role of KIAA0753 in a 
skeletal ciliopathy syndrome. The zebrafish genome shares more than 70% of their genes 
with humans and is therefore a good system to study many human diseases.112 For this study, 
the zebrafish line sa22657, which contains a premature nonsense mutation in Kiaa0753, was 
used. This line was generated within the zebrafish mutation project (ZMP),113 established by 
the Wellcome Trust Sanger Institute, and ordered from the European zebrafish resource 
center (EZRC).114 ZMP was established to generate knockout alleles of all genes in the 
zebrafish genome. Mutagenesis was performed by exposure of male zebrafish to ENU, a 
mutagenesis agent and progeny screened for mutations. Single-mutation lines have been 
established by outcrossing mutant specimens with wildtype zebrafish and genotyping. The 
sa22657 zebrafish line was maintained at the Karolinska zebrafish core facility. Zebrafish 
morphology examination was performed using a dissection microscope on five days post 
fertilisation zebrafish larvae, by staining with Alcian Blue.115 
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2.3.7 Biochemical tests for CDG 
Skeletal symptoms can occur in different metabolic conditions, such as abnormal GAG 
metabolism in dysostosis multiplex, insufficient protein glycosylation in CDG or elevated 
levels of cholesterol precursors in X-linked chondrodysplasia punctata.  
 
In study I we found potential disease-causing variants in ALG9 and evaluated the abnormal 
glycosylation pattern of transferrin in the patients and their parents. Transferrin is a highly 
abundant serum glycoprotein synthesized in the liver and is important for iron transport. It 
can be used as a biochemical marker for CDG, since they have elevated concentrations of 
carbohydrate-deficient transferrin (CDT). Glycosylation tests can be performed using CDT 
analysis to determine the defect glycosylation pattern of transferrin, using isoelectric 
focusing (IEF), capillary zone electrophoresis (CZE) or mass spectrometry. In this study we 
used liquid mass spectrometry analysis.  
 
2.3.7.1 Liquid chromatography-mass spectrometry analysis of transferrin 
CDGs are a group of disorders with defective enzymes in the biosynthesis of glycoproteins. 
The asparagine-linked (N-linked) CDGs can be tested in clinical practice by looking at the 
abnormal pattern of N-linked oligosaccharides of serum transferrin, which is the most 
sensitive marker of a defective N-glycosylation.38 In study I, serum from the affected fetuses 
was not available, therefore biopsies from frozen spleen were used instead.  
 
Liquid chromatography-mass spectrometry (LC-MS) method was used to demonstrate the 
abnormal isoforms of transferrin.116 In brief, aliquots of the samples were applied to an 
immunoaffinity column and enriched transferrin was eluted and concentrated on an analytical 
C4 column. Transferrin was eluted from the C4 column and preceded with mass spectrometry. 
Analysis of transferrin was done using frozen spleen tissue from patients and from age-
matched controls and one adult. The calculation of the ratios of mono-glycosylated/di-
glycosylated transferrin can then be compared between the samples. The ratio was 
significantly elevated in the patients compared with age-matched controls, and showed that 
the affected individuals had underglycosylated transferrin.  
 
LC-MS is a sensitive and automated method to determine the defect N-glycosylation in CDG. 
Abnormal hypoglycosylation patterns can also be seen in acquired hypoglycosylation 
(secondary), such as galactosemia, hereditary fructose intolerance or moderate to heavy 
alcohol consumption.117 CDG analysis due to a congenital disease is typically performed at 
young age so there is little risk of false positives, but the profile is the same for acquired 
hypoglycosylation and relevant clinical information may be necessary to interpret the results 
correctly.
  33 
3 RESULTS & DISCUSSION 
3.1 EXPANDING THE GENETIC SPECTRUM OF SKELETAL DYSPLASIAS 
It is not always obvious that possible pathogenic variants detected by sequencing have a role 
in bone biology and often the molecular mechanisms of conditions are not completely 
understood at the time of first report. For instance, disease-causing variants in ALG9 in study 
I and KIAA0753 in study IV were not previously known to be associated with skeletal 
abnormalities and therefore the role of these genes in bone biology were not clear. In such 
cases, several unrelated patients with the same phenotype and disease-causing variants in the 
same gene are needed to establish the proofs. Furthermore, functional validation of those 
variants and tissue expression of candidate genes are necessary, using cells cultures, tissues 
or model organisms. In study II COL2A1, study III BMPER, and study V C2CD3, 
DYNC2H1, EVC, EVC2, and WDR19 were genes already known to be involved in congenital 
skeletal disorders and bone biology, therefore easier to interpret variants in those genes in 
our patients.  
 
In some consanguineous families, such as family 2 in study I and family 1 in study IV, 
patients may have multiple pathogenic variants in known disease-associated genes. In study 
I, we found that affected fetuses from family 2 in addition to the pathogenic variants in ALG9, 
were also homozygous for potentially disease-causing variants in ANK3. Pathogenic variants 
in the ANK3 gene have been associated with autosomal recessive mental retardation 37 
(MRT37 [MIM:615493]).118 We reported the variant in ANK3 as a VUS, which most likely 
does not contribute to the phenotype of ALG9-CDG in this family.  
 
Further, two affected siblings from family 1 in study IV were homozygous for pathogenic 
variants in KIAA0753 and SLC13A5, respectively. The findings of two rare conditions rather 
than one disease with phenotypic expansion affecting these individuals, is not an unusual 
situation in consanguineous families or isolated populations.78-80 On the other hand, the 
variant in SLC13A5 in family 1 (study IV) had previously been reported to cause autosomal 
recessive early infantile epileptic encephalopathy 25 (EIEE25 [MIM:615905]), a condition 
associated with seizures, developmental disability, and teeth hypoplasia.119,120 These features 
were observed in the affected siblings, but since two unrelated families had the same 
homozygous nonsense variant in KIAA0753 and did not share the SLC13A5 variants, we 
concluded that the seizures and teeth hypoplasia were due to the homozygous SLC13A5 
variant. The developmental and speech delay are overlapping features and could be inferable 
to either one of the congenital conditions. In conclusion, in some cases with new features 
reported in association to a certain condition, there might not always be a phenotypic 
expansion of a disease, but two genetically independent conditions. Extended SNP analysis 
indicated that the two families did not have a common ancestor. 
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3.2 NOVEL DISEASE GENES CAUSING SKELETAL DYSPLASIAS  
There are numerous skeletal dysplasias with unknown genetic causes. One example is a very 
rare lethal fetal syndrome with polycystic kidneys, typical facial features and varying 
malformations with severe skeletal dysplasia were first characterized by Gillessen-Kaesbach 
et al. in 1993 and Nishimura et al in 1998.121,122 In study I, we identified three fetuses from 
two unrelated families affected with the same condition and show that this syndrome belongs 
to the most severe spectrum of N-glycosylation disorders, caused by homozygous protein 
truncating variants in ALG9.  
 
The gene, ALG9 encodes for the alpha-1,2-mannosyltransferase, an enzyme involved in the 
formation of the lipid-linked oligosaccharide (LLO) precursor of N-glycosylation. 
Previously, reported patients with ALG9-CDG had missense variants and suffered from 
intellectual disability, muscular hypotonia, microcephaly, and small renal cysts, but skeletal 
dysplasia features were not described. However, skeletal abnormalities, similar to our 
patients with ALG9-CDG have been described in ALG3- and ALG12-CDG,123-125 suggesting 
that this subset of glycosylation disorders constitutes a new diagnostic subgroup of skeletal 
dysplasias.  
 
This group of enzymes (ALG3, ALG9, and ALG12) are all important in adding mannose 
residues to the LLO in four direct sequential steps in the biosynthesis of LLOs, in the luminal 
side of the ER (Figure 2). Our study shows that protein truncating variants in ALG9 can lead 
to a lethal skeletal dysplasia and visceral malformations as the most severe phenotype 
associated with defect N-glycosylation. Another fetus, born to unrelated parents and not 
included in our study, but clinically diagnosed with similar skeletal features and previously 
reported by Kranz et al.,125 turned out to have two protein-truncating variants in ALG3 
(p.Met1? and p.Arg117*) (Hammarsjö and Zerres unpublished data).  
 
The most severe phenotype of ALG9-CDG is now included in the OMIM database as 
Gillessen-Kaesbach-Nishimura syndrome (GIKANIS [MIM:263210]) and is an important 
differential diagnosis to many fetal lethal malformation syndromes. Since our report, another 
three families (6 patients) with ALG9-CDG with abnormal N-glycosylation were reported, 
all with homozygous missense mutations and no features of severe skeletal dysplasia.126-128 
Nonetheless, even though there are only sixteen patients reported so far with ALG9-CDG the 
splice variant in our three patients is associated with a severe skeletal phenotype.  
 
Skeletal ciliopathies are a rare group of diseases, divided into different subtypes with a 
significant genetic heterogeneity and phenotypic overlap.28 Study IV revealed four patients 
and study V reported two siblings with skeletal ciliopathy phenotype and protein truncating 
variants in KIAA0753. Pathogenic variants in this gene were previously described to cause 
ciliopathies like Joubert (JBTS)129 and orofaciodigital syndrome (OFD),130 but no skeletal 
symptoms were reported in those three individuals. It is, therefore, not surprising that four of 
our patients (family 1 in study IV and family 13 in study V) showed brain abnormalities 
consistent with JBTS and fetus in study IV had features resembling OFD.  
 
Examination of the femoral growth plate from the affected fetus showed an abnormal 
architecture of the proliferative zone with lack of normal chondrocyte columns, consistent 
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with skeletal ciliopathy syndromes.31,131 Immunohistochemistry of the growth plate from 
normal age-matched control and affected fetus showed that KIAA0753 is expressed in the 
growth plate from normal fetus, but absent in the corresponding cells from the affected fetus.  
 
A zebrafish knockout model, carrying a homozygous nonsense variant in the kiaa0753 gene, 
showed classic ciliopathy phenotype with cartilage abnormalities, such as curved body and 
an abnormal head morphology due to altered cartilage patterning. The morphological 
assessment could only be performed at early developmental stages, because of early lethality 
of the larvae, not surviving beyond the first week of development. Overall, the structure of 
the skull was compressed along the anterior-posterior axis when compared to wildtype 
siblings. These results supported the involvement of KIAA0753 in the skeletal 
morphogenesis.  
 
In the small cohort of patients with KIAA0753-related syndrome that have been reported so 
far, our patients seem to have symptoms at the most severe end of the phenotypic spectrum. 
We hypothesize that the skeletal abnormalities in our patients are due to PTVs, leading to 
absent KIAA0753 expression and that the milder phenotypes of the previously reported 
patients may be due to some residual expression or milder effect of KIAA0753 function.  
 
3.3 DETECTING NEW VARIANTS IN KNOWN DISEASE GENES 
In study II, we identified a missense variant in COL2A1 (c.3655G>C, p.Asp1219His) in six 
affected family members with spondyloepiphyseal dysplasia type Stanescu (SEDSTN 
[MIM:616583]), and early onset of pain and deformities in the joints. Previous publications 
have reported similarities between SEDSTN and Czech dysplasia [MIM:609162], which is 
caused by a recurrent mutation in COL2A1 (c.823C>T, p.Arg275His), but distinguished from 
SEDSTN by the hallmarks of short 4th and 5th metatarsals.132 Study II extends the phenotypic 
spectrum of collagenopathies type II. Simultaneously another study reported three 
individuals from two unrelated families with SEDSTN and a missense variant in COL2A1 
(c.619G>A, p.Gly207Arg)133. Correlation of genotype-phenotype in SEDSTN is not possible 
so far, because only a few patients have been reported to date. It is, however, relatively well 
established that there is no good genotype-phenotype correlation in COL2A1-related skeletal 
dysplasias.134,135 
 
Most mutations in COL2A1 are in the triple helix domain and a majority affect a glycine 
residue (every third amino acid in the alpha helix is a glycine, Gly-X-Y), required for a 
correct conformation of the collagen fibre and the glycine mutations are dominant-negative. 
The type II collagenopathies are mainly inherited in an autosomal dominant matter, but in 
two studies (related publication VIII  and Barat-Houari et al.) have found a severe 
spondyloepiphyseal dysplasia congenita (SEDC [MIM 183900]) with homozygous COL2A1 
non-glycine missense mutations.136 Typically, non-glycine missense mutations, as well as 
truncating variants, are usually associated with milder phenotype. However, in these two 
families the missense mutation in heterozygosity did not result in any clinical symptoms.  
 
In study III we identified biallelic variants in BMPER in two patients with ischiospinal 
dysostosis (ISD), a disorder with abnormal ossification of the spine. The causative gene had 
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so far been unknown, but the condition was suggested to be of autosomal recessive 
inheritance and allelic to the lethal condition diaphanospondylodysostosis [MIM:608022].137 
Diaphanospondylodysostosis is caused by pathogenic variants in the BMPER gene, the 
symptoms are similar to, but more severe than those of ISD.137 Our study confirmed the 
hypothesis that ISD and diaphanospondylodysostosis were allelic disorders and extending 
the phenotypic variabilities in BMPER-related skeletal dysplasias.  
 
For patient 1, WES and segregation analyses revealed compound heterozygous mutations in 
BMPER, a highly conserved missense variant and a nonsense mutation. Patient 2 had three 
variants in BMPER, a homozygous nonsense and predicted deleterious missense variant (the 
mother carried both the nonsense and the missense variant). The missense variant was 
predicted not to be involved in this patient’s phenotype, because the nonsense variant was 
located upstream. The missense variant in patient 1 could explain her milder phenotype, but 
in background of the previously reported diaphanospondylodysostosis variants, the 
genotype-phenotype correlation is not clear for BMPER-related disorders. Subsequently, 
further reports indicated that diaphanospondylodysostosis and ISD should be considered as 
a phenotypic continuum. Legare et al. described a 9-year-old boy first classified as ISD, but 
later reclassified to diaphanospondylodysostosis due to his severe phenotype. This patient 
was compound heterozygous for a deletion that included BMPER (and eight other genes) and 
a missense variant.138 The fact that there was no renal dysplasia or Wilms tumour in the two 
patients in study III or in the patient reported by Legare et al. might contribute to their long-
term survival. Having in mind that diaphanospondylodysostosis is associated with Wilms 
tumour, individuals with ISD should be considered regular follow-up with ultrasound during 
childhood in case milder mutations lead to increased tumour risk later on.  
 
Another group of dysplasias we studied are skeletal ciliopathies which show a broad 
phenotype and genotype variability. Deleterious variants in genes coding for different ciliary 
components affect the function of the cilia in a similar way, leading to overlapping 
phenotypes and vice versa, with mutations in the same gene may lead to a broad phenotypic 
spectrum.1,28 In study V, we investigated the genetic causes of skeletal ciliopathies in 24 
unrelated individuals and identified disease-causing variants in 83% of the cohort. 
 
Strikingly, four of the patients had splice events outside the exon-intron boundaries (±2 
nucleotides) and RNA from them was needed to prove the possible pathogenicity of the 
variants. Two of the variants were seemingly synonymous and would have been discarded as 
benign if it wasn’t the fact that they segregated in the families and had an extremely low 
MAF (<0.0001). None of the interpretation software used could predict that these variants 
disrupted an exonic splicing enhancer or silencer (ESE or ESS). However, Sanger sequencing 
of cDNA showed that both synonymous variants in DYNC2H1 and KIAA0753, respectively, 
led to aberrant splicing due to exon skipping and frameshift predicted to result in NMD.77 
 
Two of the variants in close proximity (9 and 16 nucleotides upstream) to the canonical splice 
sites were shown to introduce cryptic splice sites (novel AG dinucleotides), in EVC and 
DYNC2H1. These rare intronic variants were both indicated by splice prediction tools to 
introduce new acceptor splice sites, leading to retention of intronic sequence within the 
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transcript and frameshift with predicted NMD. We pursued with Sanger sequencing of cDNA 
from fetal lung (DYNC2H1) and blood samples from heterozygous mother (EVC). 
 
All of the four patients’ splice variants were found when re-evaluating the sequence data, 
showing a need for regular reanalyses of previously unsolved cases. Although the distant 
splice variants or pathogenic synonymous variants are hard to interpret, the workflow 
changes with new in silico prediction tools and reporting disease-causing variants in 
databases (like HGMD, ClinVar, Matchmaker Exchange, DECIPHER), makes it possible to 
redeem genes and variants of unknown significance.  
 
Structural analysis showed that one patient with phenotype of mild skeletal ciliopathy had a 
1q24q25 microdeletion syndrome and another with SRTD harboured an intragenic deletion 
within DYNC2H1, which displays the importance of performing gene dose analysis and to 
include possible differential diagnoses.  
 
In four of the patients in study V no molecular diagnosis could be determined, although 
extensive analyses were performed with WGS trio sequencing. This may be attributed to the 
fact that disease-causing variants in intronic and regulatory regions are challenging to 
interpret using the current methodology or that there are novel genes not yet associated with 
the clinical conditions. Future studies, integrating RNA-sequencing may be helpful in 
identifying pathogenic variants in these patients, if RNA is made available. Here we were 
able to show that it is possible to find splice variants in RNA from blood from individuals 
with ciliopathies and it may be possible also for the unsolved cases. There have been a 
number of publications showing that there is a great increase in the diagnostic yield using 
RNA-sequencing to find variants causing abnormal splicing.139-141 Clinical correlation of 
molecular findings and clinical phenotyping is necessary to accurately interpret variants of 
unknown clinical significance, as well as to improve accuracy of bioinformatic tools.  
 
3.4 SKELETAL DYSPLASIA GENE PANEL IN A CLINICAL SETTING 
In a clinical setting we have established an in silico gene panel, to date, comprising of 466 
genes which are known to cause congenital skeletal disorders and have analysed DNA 
samples from 178 skeletal dysplasia patients (including 21 probands from study II, III, and 
V) (unpublished data). The analyses are performed using a visualization interface of genomic 
data, Scout software,142 developed by Clinical Genomics at SciLifeLab in collaboration with 
the clinical departments at Karolinska University Laboratory.  
 
In this cohort, spanning many of the groups from the skeletal nosology,1 51% of the patients 
received genetic diagnoses using WGS or WES data. The patients in the study include 
children (n=115), adults (n=33), and fetuses (n=30). There is no difference in genetic 
diagnosis outcome between the adult patients or children, but diagnostic yield is higher in the 
fetal cases (67%), which may reflect the severity of disease. 
 
Variants were found in 50 established skeletal dysplasia genes and all have been confirmed 
with Sanger sequencing and segregation analysis performed if parental samples were 
available. While there were many variants that could be classified as disease-causing, our 
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analysis revealed 10% of the variants of unknown significance in known disease genes that 
might explain the skeletal abnormalities of the patients. Further functional studies or 
extended RNA analyses are needed to confirm or discard pathogenicity. The analysis is 
mainly done as a singleton with only the affected individual, however in some cases 
sequencing of multiple samples from several unrelated families have been added to identify 
the disease-causing variants. The remaining patients without a genetic diagnosis might need 
family trio sequencing or RNA sequencing to reach the genetic diagnosis.  
 
Figure 9: The frequencies of genetic diagnoses 178 skeletal dysplasia patients using an in silico gene 
panel from WES or WGS data. The 178 patients were referred to the clinical genetics department at Karolinska 
University Hospital during 2014 to spring 2018. 91 patients had a disease-causing variant in a skeletal dysplasia 
gene, 14 patients had a VUS (that are under current investigation and has not been reported to the patients) and 
73 patients have not yet received a genetic diagnosis. LP, likely pathogenic; P, pathogenic; VUS, variant of 
unknown significance; WES, whole exome sequencing; WGS, whole genome sequencing. 
 
 
We should highlight that RNA analyses of candidate splice variants (outside the canonical 
splice site) are of great importance to be able to confirm them as disease-causing (8% of the 
positive findings). Another important aspect is that nine patients (10%) had structural 
abnormalities that explained the phenotype. In the future, this means that WGS data is of 
great importance to detect structural variants.  
 
For the consanguineous families, regions of homozygosity can help to elucidate pathogenic 
variants that are shared between family members. In this cohort 25 of the cases were from 
consanguineous families and 84% got a genetic diagnosis, all but three were homozygous for 
a pathogenic variant. These individuals were found to have known disease-causing variants 
in FGFR3, SATB2, and FLNA, indicates that even though consanguineous families have a 
higher incidence of autosomal recessive disorders, de novo variants or X-linked recessive 
variants still occur and should be considered.  
 
In the future, when costs decline and new pipelines emerge the WGS is likely to be the first-
tier analysis method, for both single gene disorders and structural variants. This will increase 
the diagnostic yield and also make it possible the re-evaluate the data from individuals with 
unsolved diagnoses and add family members for trio analysis.  
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3.5 LIMITATIONS 
A major limitation in this type of studies is that functional studies are often needed in order 
to examine the consequences of very rare variants, and to explore the underlying mechanisms 
and pathophysiological pathways of the conditions. In approximately half of the patients with 
skeletal dysplasias we fail to achieve the genetic diagnosis, despite using WES or WGS. This 
could be due to novel disease genes or variants in non-coding regions, splice aberrations, 
structural variants, repeat expansions, and epigenetic modifications.  
 
For patients where singleton WGS does not provide a genetic diagnosis, adding family 
members to the sequencing analysis may be helpful. If a novel gene is identified, increased 
sample size of patients is needed to enable the new genetic diagnosis or to make genotype-
phenotype correlations, but since the disorders often are extremely rare this is challenging. 
Matchmaker exchange and tight international collaborations makes such efforts possible (as 
in study III, IV, and V). Matchmaker exchange is an initiative to connect researchers and 
match patients with the same phenotype and genetic architecture for interpretation.143,144 
Another strategy to elucidate the genetic cause in patients with an unsolved genetic skeletal 
dysplasia presenting with a known phenotype is to search for possibly pathogenic variants in 
genes coding for molecules in the same pathways. This was done when we recently identified 
a novel gene behind Stuwe-Wiedemann syndrome (STWS [MIM:601559]) (Grigelioniene, 
Hammarsjö et al. manuscript in preparation). Another way to solve human genetic diagnoses 
is to recognize the malformation pattern in experimental animals and draw parallels with 
human conditions. Some skeletal dysplasias were genetically solved with such a hypothesis 
for example TRIP11 mutations in achondrogenesis type 1A (ACG1A [MIM:200600]) were 
identified when it was recognized that Trip11-null mice shared skeletal similarities with 
ACG1A patients.145 
 
How to report variants of unknown significance back to an affected family is not always 
simple, but ACMG states a clinical analysis of 56 genes that should be reported to the 
patient/family irrespective of age. Fetal and newborn screening is not included in this list.146 
The genes included are associated with conditions that are preventable or treatable when 
detected early enough, such as cancer susceptibility syndromes, cardiomyopathies, or aortic 
and intracranial aneurysms. The variants are reported back as secondary findings and should 
described as pathogenic or expected pathogenic based on the type of variation. Green et. al146 
calculated that around 1% of the clinical WES/WGS will result in incidental finding unrelated 
to condition of the patient.  
 
Even if we mainly use in silico gene panels from WGS data, we still encounter incidental 
findings that are not related to the phenotype that are classified as possibly pathogenic. Often 
it is one variant that is associated with a recessive skeletal condition, i.e. heterozygous carrier 
status that we don’t report to the patient. In our study of 178 skeletal dysplasia patients, we 
had one family with a fetus with severe OI and a de novo variant in COL1A1. Furthermore, 
we identified a pathogenic variant in COL11A2 associated with autosomal dominant deafness 
with onset in middle age. After genetic counselling with the family and ethical 
considerations, we chose to report this variant to the family, since it might spare the carriers 
from unnecessary medical examinations at onset and maybe important when selecting 
occupation, and/or adjusting life style.  
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There are still many skeletal dysplasia patients in our clinical cohort with not yet identified 
genetic background. It might be due to another layer of complexity that we are not clinically 
ready to approach, i.e. the non-coding variants in the regulatory elements or the variants 
affecting the recognition of splice sites. Complex regulatory mechanisms of skeletal 
development, translational, and epigenetic regulation, as well as post-transcriptional 
modification are processes which will be highlighted by emerging new molecular techniques.  
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4 CONCLUDING REMARKS & FUTURE PERSPECTIVES 
Complex networks are vital for the processes of bone growth and remodelling, and genetic 
studies of skeletal disorders have shed light on the signalling pathways involved. Since most 
of the skeletal dysplasias are caused by mutations in a single gene, they represent 
‘experiments of nature’ with great potential for advancing the understanding of the specific 
genes involved in skeletal development. The details how the products of these genes interact 
in complex networks are still emerging. As indicated, skeletal radiology and pattern 
recognition are essential to group and recognize the conditions. Compared to facial 
dysmorphology, skeletal pattern recognition is an easier instrument to classify the conditions, 
because the radiographic morphology is less influenced by ethnical variations. 
 
As shown for all the studies in this thesis, the genetic analyses are based on MPS technology 
and the advances in technology have changed the field of clinical genetics. From the 
beginning of 2014 the data was obtained mainly with WES, due to cost and amount of DNA 
needed. But as time passes the WGS costs have decreased and is now the preferred strategy 
(almost all-in-one-analysis). The innovation of new annotation and prediction tools that will 
combine and interpret the data will lead to increased number of solved genetic diagnoses. 
Tight collaboration between the clinicians, molecular biologists, and bioinformaticians will 
help to further improve the bioinformatic pipelines.  
 
WGS is a fast and reliable method to find the causative variant for not only skeletal 
dysplasias, but for all Mendelian disorders. Already now the WGS data provide us with 
information about structural abnormalities and sequence variants with in silico prediction 
tools, evolutionary conservation, and allele frequency from large databases to interpret the 
variants in relation to the disease phenotype. In the near future, WGS will most likely replace 
the conventional techniques used in a clinical genetics laboratory today, such as karyotyping, 
aCGH, MLPA, and Sanger sequencing. Those methods will be used more to verify the WGS 
results.  
 
Long-read sequencing is an upcoming technology that will enable us to resolve compound 
heterozygous variants without the need for segregation analysis, as well as finding middle-
sized structural variants missed today due to technical reasons. RNA-sequencing and 
proteomics will also be valuable to elucidate which genomic variants actually affect splicing 
and will contribute in genotype-phenotype correlations. Although RNA-sequencing data is 
limited to the patient material and time-point it was collected, it could be used to address the 
problem. RNA from affected tissue is preferential to ensure that the gene involved in the 
pathogenesis is expressed. However, many genes are expressed in multiple tissues and we 
have seen that examining RNA extracted from blood is sufficient to show aberrant splicing 
in several cilia encoding genes. Another source to examine RNA would be from fibroblast 
cultures, since skeletal and cartilage tissues are difficult to obtain. 
 
Genes important for skeletal formation are not only conserved in different species on the 
sequence level but also in their molecular function, which makes species like zebrafish and 
mice suitable to model human skeletal disorders. Discovering signalling pathways and 
molecules important in skeletal dysplasias can also be studied in a cellular level and the 
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transgenic animals or cells treated with different substances to target the affected molecular 
pathways. The CRISPR/Cas9 technology has been of great importance to target genes and 
introduce specific variants, in order to mimic disease in model organisms.  
 
The genetic studies of monogenic diseases increase our understanding of the pathogenesis of 
skeletal dysplasias and the roles of these genes in normal skeletal development. New findings 
lead to a picture of a complicated network and reveal targets for potential new drug therapies, 
not only for rare skeletal disorders but also for common conditions that display the same or 
similar pathogenetic mechanisms, such as osteoporosis, scoliosis, and arthritis. One of the 
main challenges for the future are to map the genetic pathways in detail and describe the 
pathophysiological processes behind the skeletal diseases and find the possibilities to develop 
novel therapeutic strategies. There have been some convincing studies in both humans and 
mice to increase bone mass with monoclonal antibodies against sclerostin147 and mice with 
achondroplasia have been treated with a CNP analogue (CNP antagonize the Fgfr3 
signalling).148 
 
Genetics are displayed in different layers, from the genomic DNA, to the more hidden 
information that influence inheritance, development, and disease, such as the transcriptome, 
the proteome, and epigenetics. Also, the non-coding RNAs are very important for the normal 
development to function properly. At first, the non-coding DNA was thought to make “no 
sense” and only the DNA coding for proteins were important, but as it appears the molecular 
biology is unfolding and more complex regulatory mechanisms are identified.  
 
In the future, with WGS data from an individual we could also include an analysis to make a 
report of variants that could be of interest to characterize a patients’ response to treatment 
and a list of common disease-variants, such as CFTR with a high allele frequency in our 
population, to avoid common congenital disorders in a specific population. Further, the 
ACMG guidelines states that secondary findings that are preventative or treatable for early 
detection should be brought back to the patient, regardless of autonomy because of family 
benefit.  
 
This thesis has shed light on the molecular background on some of the skeletal dysplasias 
and given many patients their genetic diagnosis. In the future, I hope that this work add value 
to experimental work to develop and optimize treatment for skeletal dysplasias.   
 44 
5 POPULÄRVETENSKAPLIG SAMMANFATTNING 
Medfödda skelettsjukdomar innebär att skelettet har en onormal form och/eller hållfasthet, 
med varierande symptom som omfattar allt från fosterdöd till kortvuxenhet i vuxen ålder. 
Många diagnoser är associerade med andra symptom såsom neurologiska komplikationer, 
missbildningar och skador på inre organ. De orsakas av förändringar i arvsanlag (gener) som 
styr skelettets utveckling. Symptombilden varierar beroende på vilken gen som orsakar 
sjukdomen, dvs vilken gen som är muterad. Kliniska diagnosen kan försvåras för många 
skelettsjukdomar, då mutationer i en gen kan leda till flera olika sjukdomar och mutationer i 
flera olika gener kan leda till en och samma diagnos.  
 
Skelettsjukdomar är i det stora hela ganska vanliga i en population och drabbar cirka en på 
tre tusen individer, men varje enskild diagnos är sällsynt och det saknas ofta klinisk kunskap 
om komplikationer och behandling. Man säger att skelettsjukdomar är en heterogen grupp då 
det finns en stor klinisk variabilitet där diagnosen ställs med kliniska fynd och röntgen. I 
möjligaste mån vill man även bekräfta diagnosen genetiskt för att på så sätt vara säker på att 
patienten får optimal medicinsk uppföljning.  
 
Den nuvarande klassificeringen av medfödda skelettsjukdomar från 2015 omfattas av 436 
diagnoser fördelade i 42 grupper. För många av dessa diagnoser är den genetiska orsaken 
ännu inte identifierad. I klassificeringen är 364 gener beskrivna, men vi känner idag till 
ungefär 460 gener där mutationer i dessa kan orsaka en skelettsjukdom. Tekniken för att hitta 
dessa mutationer bygger framför allt på massiv parallell sekvensering och är en mycket 
effektiv metod för att hitta den genetiska orsaken hos patienter med sällsynta genetiska 
sjukdomar, inte bara för sjukdomar som drabbar skelettet.  
 
Människan har ungefär 21 000 gener, som är uppbyggda av DNA molekyler och utgör 
instruktionerna för att skapa liv. Det är denna genetiska kod som otroligt nog endast består 
av fyra kvävebaser; adenin (A), cytosin (C), guanin (G) och tymin (T) som förs vidare från 
generation till generation. Med storskalig sekvensering kan man bestämma ordningen på i 
stort sett alla tre miljarder baser i den genetiska koden (även kallad genomet). Det gör att det 
nu är möjligt att jämföra DNA från en sjuk individ med en referens bestående av friska 
individer. Användandet av storskalig sekvensering har lett till att arvsmassan hos mer än 
hundra tusen individer har kartlagts och användningsområdet är stort, men framför allt är den 
genetiska variationen tillgänglig för att avgöra vilka varianter som är mutationer och leder 
till en genetisk sjukdom. Medan DNA finns i cellens kärna och lagrar den genetiska koden, 
översätter RNA information från den genetiska koden för att skapa ett funktionellt protein.  
 
I den här studien har vi identifierat gener som är viktiga i skelettets uppbyggnad. Det har vi 
gjort genom att sekvensera alla gener hos flera individer från samma familj, för att kunna 
skilja de sjukdomsorsakande mutationerna från normal variation (de varianter som gör oss 
unika). I studie I identifierade vi mutationer i ALG9 genen hos två familjer som drabbats av 
upprepad fosterdöd, dessa var nedärvda från varsin förälder och således är en autosomalt 
recessiv sjukdom. Det innebär att dessa två familjer har en hög upprepningsrisk att få barn 
med denna svåra skelettsjukdom. Även i studie IV hittade vi mutationer i en gen, KIAA0753, 
som inte tidigare varit associerad med skelettavvikelser. De drabbade individerna hade en 
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bred variabilitet, från fosterdöd till mycket smal bröstkorg, korta ben och armar och 
utvecklingsförsening. Både ALG9 och KIAA0753 var tidigare kända att orsaka andra 
genetiska sjukdomar utan skelettpåverkan.  
 
I ytterligare två studier har vi hittat mutationer i tidigare kända skelettgener, men där genetisk 
orsak för skelettsjukdomen varit okänd. I studie II har vi beskrivit symptom hos en stor 
svensk familj med sju drabbade individer med spondyloepifysär dysplasi typ Stanescu och 
visat att det beror på en mutation i genen COL2A1, som kodar för kollagen och är viktig i 
stabiliteten av brosk/ben. I studie III har vi två patienter drabbade av ischiospinal dysostos 
(ISD) med mutationer i BMPER. Genen är känd att orsaka en dödlig skelettdysplasi, 
diaphanospondylodysostos, men våra patienter är två respektive sjutton år gamla. Vi visar 
med denna studie att ISD och diaphanospondylodysostos är en del av samma 
sjukdomsspektrum och orsakas av mutationer i samma gen.  
 
I studie V genomfördes storskalig sekvensering för att hitta den genetiska orsaken hos 24 
patienter med skelettfenotyp karaktäriserad av korta revben och smal bröstkorg, samt korta 
rörben. Sjukdomen nedärvs autosomalt recessivt. Vi identifierade mutationer hos 20 av de 
24 individerna (83%), där det visade sig att fyra av mutationerna behövde analyseras med 
hjälp av RNA för att visa att de var så kallade splitsningsmutationer, som förutses ge ett 
felaktigt uttryck av proteinet. 
 
Vidare har vi undersökt närmare 200 individer med medfödda skelettsjukdomar med 
storskalig sekvensering av hela genomet, men där vi egentligen bara analyserar en panel av 
skelettgener. Vi hittar då den molekylära orsaken i ungefär hälften av fallen. De flesta 
individerna med genetisk diagnos har mindre sekvensavvikelser, såsom ett utbyte av 
kvävebas, men även gendosavvikelser (för mycket eller för lite genetiskt material) och 
inversioner som bryter genens funktion har hittats (se figur 3). Flertalet av de individer utan 
mutationer i de kända generna har unika sjukdomstillstånd, som utgör en grund för fortsatt 
analys för att hitta nya varianter eller gener som orsakar sjukdomen. För att analysera 
konsekvenserna och kartlägga mekanismer av nya genetiska varianter kan sjukdomsmodeller 
eller RNA studeras, såsom zebrafisk i studie IV och RNA-sekvensering i studie I och studie 
V.  
 
Syftet med denna studie har varit att studera genetiken bakom medfödda skelettsjukdomar, 
där de nya genetiska orsakerna som upptäckts ökar kunskapen om de enskilda diagnoserna 
och till en ökad förståelse av nya sjukdomsmekanismer för reglering av skelettets tillväxt. På 
lång sikt kan den nya kunskapen leda till utveckling av nya läkemedel för behandling av 
vanliga skelettsjukdomar som benskörhet och artros. En snabb implementering av resultaten 
gör att en molekylär diagnos kan användas vid familjeplanering för de drabbade familjerna 
för att undvika upprepning av samma diagnos i familjen.  
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